Boston Partners grew its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 27.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 536,262 shares of the medical instruments supplier's stock after acquiring an additional 115,506 shares during the period. Boston Partners owned 1.07% of Haemonetics worth $41,485,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Arizona State Retirement System lifted its holdings in shares of Haemonetics by 1.2% in the fourth quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock worth $1,160,000 after buying an additional 181 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 240 shares during the period. HighTower Advisors LLC lifted its stake in Haemonetics by 7.8% in the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after purchasing an additional 244 shares in the last quarter. Segall Bryant & Hamill LLC boosted its holdings in Haemonetics by 0.7% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 62,621 shares of the medical instruments supplier's stock valued at $5,033,000 after purchasing an additional 407 shares during the period. Finally, Isthmus Partners LLC grew its position in shares of Haemonetics by 1.1% during the 4th quarter. Isthmus Partners LLC now owns 40,220 shares of the medical instruments supplier's stock valued at $3,140,000 after purchasing an additional 450 shares in the last quarter. 99.67% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
HAE has been the topic of several recent analyst reports. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and lowered their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. Needham & Company LLC lowered their target price on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. Raymond James reiterated a "strong-buy" rating and set a $115.00 target price (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an "overweight" rating and a $116.00 price target on the stock. Finally, Barrington Research dropped their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $101.22.
Get Our Latest Report on HAE
Haemonetics Trading Up 0.9 %
Shares of Haemonetics stock traded up $0.55 on Monday, hitting $64.55. The stock had a trading volume of 365,867 shares, compared to its average volume of 649,946. The stock's 50-day simple moving average is $67.29 and its two-hundred day simple moving average is $75.03. Haemonetics Co. has a one year low of $58.80 and a one year high of $97.97. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of 25.41, a PEG ratio of 1.11 and a beta of 0.43.
Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, sell-side analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.
About Haemonetics
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Read More
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
